Allergic diseases and malignancies cause a lot of morbidity, mortality and high costs for healthcare systems. An inverse association between allergy and cancer has been suspected for a long time, but even despite extensive research no general relationship has been determined. This review comprises 32 epidemiological studies published between 1960 and 2011 and draws conclusions regarding relationships between specific types of cancer and allergic diseases. On the one hand, inflammatory reactions in the course of allergy can support carcinogenesis but are limited to specific areas, whereas on the other hand systemic effects in terms of enhanced immunosurveillance can prevent cancer.

Keywords:
Allergy, Cancer, Inflammation, Immunosurveillance
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2.
Gaber E, Wildner M: Sterblichkeit, Todesursachen und regionale Unterschiede. Gesundheitsberichterstattung des Bundes. Berlin, Robert Koch-Institut, 2011.
3.
American Cancer Society: Cancer Facts & Figures 2010. Atlanta, American Cancer Society, 2010.
4.
Hermann-Kunz E: Allergische Krankheiten in Deutschland. Ergebnisse einer repräsentativen Studie. Gesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 2000;43:400–406.
5.
Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–478.
6.
Mann C: Observational research methods – research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003;20:54–60.
7.
Rothman KJ, Greenland S, Lash TL: Modern Epidemiology, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2008.
8.
Szklo M, Nieto FJ: Epidemiology: beyond the basics, ed 2. Sudbury, Jones & Bartlett, 2007.
9.
Fisherman EW: Does the allergic diathesis influence malignancy? J Allergy 1960;31:74–78.
10.
Mackay WD: The incidence of allergic disorders and cancer. Br J Cancer 1966;20:434–437.
11.
Allegra J, Lipton A, Harvey H, Luderer J, Brenner D, Mortel R, Demers L, Gillin M, White D, Trautlein J: Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res 1976;36:3225–3226.
12.
Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE: Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005;162:212–221.
13.
Vena JE, Bona JR, Byers TE: Allergy-related diseases and cancer: an inverse association. Am J Epidemiol 1985;122:66–74.
14.
Mills PK, Beeson WL, Fraser GE, Phillips RL: Allergy and cancer: organ site-specific results from the Adventist Health Study. Am J Epidemiol 1992;136:287–295.
15.
Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN: Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan. Int J Cancer 2012;130:1160–1167.
16.
McWhorter WP: Allergy and risk of cancer: a prospective study using NHANESI followup data. Cancer 1988;62:451–455.
17.
Vesterinen E, Pukkala E, Timonen T, Aromaa A: Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 1993;22:976–982.
18.
González-Pérez A, Fernández-Vidaurre C, Rueda A, Rivero E, García Rodríguez LA: Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf 2006;15:131–138.
19.
Olesen AB, Engholm G, Storm HH, Thestrup-Pedersen K: The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol 2005;125:445–449.
20.
Hagströmer L, Ye W, Nyrén O, Emtestam L: Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005;141:1123–1127.
21.
Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM: Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol 2010;163:1036–1043.
22.
Shapiro S, Heinonen OP, Siskind V: Cancer and allergy. Cancer 1971;28:396–400.
23.
Eriksson NE, Mikoczy Z, Hagmar L: Cancer incidence in 13,811 patients skin tested for allergy. J Invest Allergol Clin Immunol 2005;15:161–166.
24.
Lindelöf B, Granath F, Tengvall-Linder M, Ekbom A: Allergy and cancer. Allergy 2005;60:1116–1120.
25.
Pompei R, Lampis G, Ingianni A, Nonnis D, Ionta MT, Massidda B: Allergy and tumour outcome after primary cancer therapy. Int Arch Allergy Immunol 2004;133:174–178.
26.
Holly EA, Eberle CA, Bracci PM: Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol 2003;158:432–441.
27.
Eppel A, Cotterchio M, Gallinger S: Allergies are associated with reduced pancreas cancer risk: a population-based case-control study in Ontario, Canada. Int J Cancer 2007;121:2241–2245.
28.
Olson SH, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, Ludwig E, Zauber AG, Kurtz RC: Allergies, variants in IL-4 and IL-4Rα genes, and risk of pancreatic cancer. Cancer Detect Prev 2007;31:345–351.
29.
Olson SH, Chou JF, Ludwig E, O’Reilly E, Allen PJ, Jarnagin WR, Bayuga S, Simon J, Gonen M, Reisacher WR, Kurtz RC: Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 2010;127:2412–2419.
30.
Santillan AA, Camargo CA Jr, Colditz GA: A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003;14:327–334.
31.
Negri E, Bosetti C, La Vecchia C, Levi F, Tomei F, Franceschi S: Allergy and other selected diseases and risk of colorectal cancer. Eur J Cancer 1999;35:1838–1841.
32.
Bosetti C, Talamini R, Franceschi S, Negri E, Giacosa A, La Vecchia C: Allergy and the risk of selected digestive and laryngeal neoplasms. Eur J Cancer Prev 2004;13:173–176.
33.
Prizment AE, Folsom AR, Cerhan JR, Flood A, Ross JA, Anderson KE: History of allergy and reduced incidence of colorectal cancer, Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 2007;16:2357–2362.
34.
Talbot-Smith A, Fritschi L, Divitini ML, Mallon DFJ, Knuiman MW: Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003;157:606–612.
35.
Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD: History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002;99:252–259.
36.
Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, Van Tongeren M, Muir KR: History of allergies and risk of glioma in adults. Int J Cancer 2006;119:2165–2172.
37.
Wigertz A, Lönn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, Johansen C, Klæboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M: Allergic conditions and brain tumor risk. Am J Epidemiol 2007;166:941–950.
38.
Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Sampson JH, Chang S, Prados M, Wiencke JK, Wrensch M: IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer 2009;125:680–687.
39.
Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, Black PM, Yu H, Schildkraut JM, Claus EB: Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer 2011;129:1932–1939.
40.
Wang H, Rothenbacher D, Löw M, Stegmaier C, Brenner H, Diepgen TL: Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum. Int J Cancer 2006;119:695–701.
41.
Wang H, Diepgen TL: Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005;60:1098–1111.
42.
Turner MC, Chen Y, Krewski D, Ghadirian P: An overview of the association between allergy and cancer. Int J Cancer 2006;118:3124–3132.
43.
Severi G, Baglietto L, Muller DC, English DR, Jenkins MA, Abramson MJ, Douglass JA, Hopper JL, Giles GG: Asthma, asthma medications, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:2318–2324.
44.
Scheurer ME, Amirian ES, Davlin SL, Rice T, Wrensch M, Bondy ML: Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer 2011;129:2290–2296.
45.
Arumugam T, Ramachandran V, Logsdon CD: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806–1818.
46.
Mesdaghi M, Vodjgani M, Salehi E, Hadjati J, Sarrafnejad A, Bidad K, Berjisian F: Natural killer cells in allergic rhinitis patients and nonatopic controls. Int Arch Allergy Immunol 2010;153:234–238.
47.
Jakóbisiak M, Lasek W, Golab J: Natural mechanisms protecting against cancer. Immunol Lett 2003;90:103–122.
48.
Morse MA, Lyerly HK, Clay TM, Abdel-Wahab O, Chui SY, Garst J, Gollob J, Grossi PM, Kalady M, Mosca PJ, Onaitis M, Sampson JH, Seigler HF, Toloza EM, Tyler D, Vieweg J, Yang Y: How does the immune system attack cancer? Curr Probl Surg 2004;41:15–132.
49.
Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137–148.
50.
Munitz A, Levi-Schaffer F: Eosinophils: ‘new’ roles for ‘old’ cells. Allergy 2004;59:268–275.
51.
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H: AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008;63:1255–1266.
52.
Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2: role of interleukin 5. Int J Cancer 1993;54:8–15.
53.
Ellyard JI, Simson L, Parish CR: Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007;70:1–11.
54.
Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ: Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008;57:247–263.
55.
Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH: Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008;153:401–409.
56.
Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG: IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 2001;61:5517–5522.
57.
Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP: Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039–1046.
58.
Pinto FCH, Menezes GB, Moura SAL, Cassali GD, Teixeira MM, Cara DC: Induction of apoptosis in tumor cells as a mechanism of tumor growth reduction in allergic mice. Pathol Res Pract 2009;205:559–567.
59.
Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860–867.
60.
Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211–217.
61.
Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P: Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev. 2005;14:1908–1916.
62.
Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau MC, Roberfroid M, Rowland I: Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80:147–171.
63.
Pachter JS, De Vries HE, Fabry Z: The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62:593–604.
64.
Linos E, Raine T, Alonso A, Michaud D: Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007;99:1544–1550.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.